Archives
RCT | Talimogene Laherparepvec plus Pembrolizumab not better than placebo-Pembrolizumab in patients with advanced melanoma.
26 Aug, 2022 | 13:09h | UTC
Systematic Review | Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
26 Aug, 2022 | 13:10h | UTC
A review of more than 2000 cases of site-specific pelvic endometriosis rates by MRI: a guide to minimizing under/overdiagnosis non-invasively.
26 Aug, 2022 | 13:08h | UTC
A Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial.
26 Aug, 2022 | 13:08h | UTCOriginal Study: Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury – New England Journal of Medicine
Related:
Review | Multimodality imaging of renal lymphoma and its mimics.
26 Aug, 2022 | 13:07h | UTCMultimodality imaging of renal lymphoma and its mimics – Insights into Imaging
Single-arm phase 2 study | Rituximab, Lenalidomide, and Ibrutinib in patients with newly diagnosed Large B-Cell Lymphoma.
26 Aug, 2022 | 13:05h | UTCSmart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase II study in 60 pts with newly diagnosed DLBCL, the ORR after 2 cycles of rituximab, lenalidomide & ibrutinib was 86.2%, with a CR rate of 94.5% after a further 6 cycles together with standard chemo; 2-yr PFS & OS were 91.3% & 96.6%, respectively https://t.co/lvNs8DFSYp
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022
Multi-nuclear magnetic resonance spectroscopy: state of the art and future directions.
26 Aug, 2022 | 13:06h | UTC
Long-term results of a RCT | Lenalidomide plus Rituximab vs. Rituximab-chemotherapy followed by Rituximab maintenance in untreated advanced Follicular Lymphoma.
26 Aug, 2022 | 13:03h | UTCCommentaries:
Commentary on Twitter
6-year update from the phase III RELEVANCE trial of lenalidomide-rituximab versus rituximab-chemotherapy in previously untreated patients with advanced-stage follicular lymphoma demonstrates very similar durable efficacy and safety: https://t.co/rMeA2tOoO6 #lymsm #hemeonc
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022
M-A | Family history of psychiatric disorders as a risk factor for maternal postpartum depression.
26 Aug, 2022 | 13:04h | UTCFamily History of Psychiatric Disorders as a Risk Factor for Maternal Postpartum Depression: A Systematic Review and Meta-analysis – JAMA Psychiatry (link to abstract – $ for full-text)
Commentaries:
Family History of Mental Illness Ups Odds for Postpartum Depression – HealthDay
Commentary on Twitter
Based on 26 studies from 18 countries, this systematic review and meta-analysis highlighted that mothers with a family history of any psychiatric disorder had an almost doubled risk of developing postpartum #depression compared to mothers without. https://t.co/zEJd6YHe71
— JAMA Psychiatry (@JAMAPsych) August 20, 2022
Triple negative breast cancer: pitfalls and progress.
26 Aug, 2022 | 13:02h | UTCTriple negative breast cancer: Pitfalls and progress – npj Breast Cancer
Randomized Crossover Trial | In patients with diabetic neuropathic pain, amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective.
25 Aug, 2022 | 12:14h | UTC
RCT | In patients with low-risk nasopharyngeal carcinoma, radiotherapy alone was noninferior to radiotherapy plus concurrent chemoradiotherapy on survival without disease relapse at 3 years.
25 Aug, 2022 | 12:13h | UTCEffect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial – JAMA (free for a limited period)
Video Editor’s Note: Radiotherapy With vs Without Chemoradiotherapy in Low-risk Nasopharyngeal Carcinoma – JAMA
Editorial | Keeping meta-analyses fresh.
25 Aug, 2022 | 12:09h | UTCKeeping Meta-analyses Fresh – JAMA Network Open
RCT | Enoxaparin (40 mg/d) is superior to aspirin (100 mg/d) for the prevention of thromboembolism in patients undergoing hip or knee arthroplasty.
25 Aug, 2022 | 12:12h | UTCEffect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial – JAMA (free for a limited period)
Editorial: Thromboprophylaxis After Hip or Knee Arthroplasty – JAMA
Commentary on Twitter
In patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic venous thromboembolism (VTE), including below-knee VTE. #Research https://t.co/CdlbAgBttJ
— JAMA (@JAMA_current) August 23, 2022
RCT | In patients with alcohol use disorder, the percentage of heavy drinking days was reduced with a psychedelic drug.
25 Aug, 2022 | 12:10h | UTCNews Release: Psychedelic drug therapy may help treat alcohol addiction – NYU Grossman School of Medicine
Commentary on Twitter:
In adults with alcohol-dependence, two doses of #psilocybin in combination with psychotherapy produced robust decreases in drinking relative to the outcomes observed with placebo and psychotherapy. https://t.co/M8PCbfwmWn #Research pic.twitter.com/duCJUL0jhx
— JAMA Psychiatry (@JAMAPsych) August 24, 2022
Retrospective Cohort Study | Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge.
25 Aug, 2022 | 12:08h | UTC
Commentary on Twitter
During the clinical rollout of nirmatrelvir in Israel in early 2022, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen among patients at highest risk for Covid-19 progression, such as those 65+. https://t.co/O6CxzDdIfH pic.twitter.com/ccCaCCh15i
— NEJM (@NEJM) August 24, 2022
Hospitalizations for unintentional cannabis poisonings among Canadian children surged after legalization.
25 Aug, 2022 | 12:07h | UTCOriginal Study: Edible Cannabis Legalization and Unintentional Poisonings in Children – New England Journal of Medicine ($)
Consensus Document | Management of decompensated cirrhosis in the surgical ICU.
25 Aug, 2022 | 12:05h | UTC
Commentary on Twitter
#TSACOTuesday 🔥 !
Check out what the AAST Critical Care Committee has to say about the managing Decompensated Cirrhotics in the SICU! https://t.co/lKVn9Y50xO pic.twitter.com/A4MQzaDvTk— Trauma Surgery & Acute Care Open (TSACO) (@TSACO_AAST) August 2, 2022
RCTs | Ublituximab vs. Teriflunomide in relapsing multiple sclerosis.
25 Aug, 2022 | 12:04h | UTCUblituximab versus Teriflunomide in Relapsing Multiple Sclerosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In two parallel randomized trials in patients with MS, ublituximab resulted in lower relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not affect disability. https://t.co/fpdtYhTNER pic.twitter.com/EPJEetSVdS
— NEJM (@NEJM) August 24, 2022
RCT | Olokizumab vs. Placebo or Adalimumab in rheumatoid arthritis.
25 Aug, 2022 | 12:04h | UTCOlokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Novel IL-6 Blocker Matches Humira in Rheumatoid Arthritis – MedPage Today (free registration required)
Cohort Study | Characteristics of prescription opioid analgesics in pregnancy and risk of neonatal opioid withdrawal syndrome in newborns.
25 Aug, 2022 | 12:02h | UTC
Cohort Study | Association between changes in alcohol consumption and cancer risk.
25 Aug, 2022 | 12:03h | UTCAssociation Between Changes in Alcohol Consumption and Cancer Risk – JAMA Network Open
Invited Commentary: Reducing Alcohol Use for Cancer Prevention – JAMA Network Open
Network M-A | Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer.
25 Aug, 2022 | 12:01h | UTC
Expert Analysis | Clinical applications of cardiac magnetic resonance imaging in pericardial diseases.
25 Aug, 2022 | 11:59h | UTCRelated: Case Series: Cardiac magnetic resonance in the assessment of pericardial abnormalities.
Phase 2 RCT | Adjuvant intravesical chemohyperthermia not better than passive chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer.
25 Aug, 2022 | 12:00h | UTC
Commentary on Twitter
No benefit of adjuvant intravesical hyperthermic chemo (CHT) for intermediate-risk non–muscle-invasive bladder cancer
🔸DFS @ 24 mo was 61% vs 60%
🔸Patients treated with CHT were less likely to complete their treatment @EUplatinum @OncoAlert @Uroweb https://t.co/q8lB2MxBFf pic.twitter.com/E8Ay5hirBb— Yüksel Ürün (@DrYukselUrun) August 22, 2022
Under a Creative Commons license